Evidence map›Paper›PMID 36830989›Full record

ArticleBiomedicines2023

Synthesis, Characterization and Biocompatibility Evaluation of Novel Chitosan Lipid Micro-Systems for Modified Release of Diclofenac Sodium.

Ana-Maria Raluca Pauna, Liliana Mititelu Tartau, Maria Bogdan, Andreea-Daniela Meca, Gratiela Eliza Popa, Ana Maria Pelin, Cristian Ilie Drochioi, Daniela Angelica Pricop, Liliana Lacramioara Pavel

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Formulation of silymarin surface modified vesicles: In vitro characterization to cell viability assessment.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ana-Maria Raluca PaunaDepartment of Pharmacology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Liliana Mititelu TartauDepartment of Pharmacology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0001-7983-3811
Maria BogdanDepartment of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy, 200349 Craiova, Romania.ORCID 0000-0001-8089-1787
Andreea-Daniela MecaDepartment of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy, 200349 Craiova, Romania.ORCID 0000-0002-6890-049X
Gratiela Eliza PopaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Ana Maria PelinDepartment of Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University, 800010 Galați, Romania.ORCID 0000-0002-5568-3780
Cristian Ilie DrochioiSurgical Department, Faculty of Dental Medicine, University of Medicine and Pharmacy, 700115 Iasi, Romania.
Daniela Angelica PricopDepartment of Physics, Faculty of Physics, "Al. I. Cuza" University, 700506 Iasi, Romania.ORCID 0000-0001-6651-9911
Liliana Lacramioara PavelDepartment of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University, 800010 Galați, Romania.
Grigore T. Popa University of Medicine and Pharmacy · RO"Dunarea de Jos" University of Galati · ROUniversity of Medicine and Pharmacy of Craiova · ROAlexandru Ioan Cuza University · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of our study was the obtaining, characterization and biocompatibility estimation of novel carrier systems for diclofenac. Diclofenac is a potent nonsteroidal anti-inflammatory drug with frequent gastrointestinal side effects, impairing the quality of the patient's life. Original diclofenac-loaded micro-vesicles coated with chitosan were prepared and physico-chemical analyzed. We investigated their in vitro hemocompatibility and in vivo biocompatibility in rats. The animals were treated orally as follows: group 1 (Control): distilled water 0.3 mL/100 g body weight; Group 2 (CHIT): 0.3 mL/100 g body weight 0.5% chitosan solution; Group 3 (DCF): 15 mg/kg body weight diclofenac; Group 4 (DCF-ves): lipid vesicles loaded with diclofenac 15 mg/kg body weight. Blood samples were collected for assessing: red blood cells, hemoglobin, hematocrit and leukocyte formula. A series of specific parameters of the liver and kidney function, some markers of immune defense, as well as the activity of some enzymes involved in oxidative processes, were also investigated. At the end of the experiment, the animals were sacrificed and fragments of liver, kidney and stomach were collected for histopathological examination. No blood hemolysis was evidenced by the in vitro test with the administration of diclofenac vesicles. The animals treated with diclofenac lipid vesicles stabilized with chitosan did not display any notable differences in their hematological and biochemical profile compared to control animals. These data correlated with the histological results, which showed the absence of architectural changes in the examined tissues. Biological in vitro and in vivo evaluation revealed that the microvesicles containing diclofenac are biocompatible, with potential to be used as delivery systems to modify the drug release, thus making them an attractive candidate for biomedical applications.

Indexed as

biocompatibilitycharacterizationchitosandiclofenaclipid vesiclesrats

Identifiers

PMID36830989
PMCPMC9953466
OpenAlexW4319298307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.